It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Gallbladder carcinoma (GBC) is a biliary tract cancer with few treatment options and poor prognosis. Radical surgery is the only potentially curative treatment option but most patients diagnosed with GBC are unresectable. Thus, there is a great need for the development of new treatment options including targeted therapy. Here, we aimed at identifying deregulated miRNAs and affected pathways involved in GBC development and progression. We performed global miRNA profiling of 40 GBC and 8 normal gallbladder tissues and identified large differences with 30% of miRNAs being differentially expressed (false discovery rate: FDR < 0.001). We found 24 miRNAs to be differentially regulated in GBC with poor outcome (p < 0.05) of which miR-145-5p was the most downregulated miRNA. Overexpression of miR-145-5p significantly reduced cell proliferation and colony formation. Gene expression analysis of cells expressing miR-145-5p mimics revealed activation of the Signal transducer and activator of transcription 1 (STAT1) signaling pathway which is mainly tumor suppressive. Furthermore, the activation of STAT1 by miR-145-5p was specifically observed in gallbladder carcinoma and cholangiocarcinoma but not in hepatocellular carcinoma cells. The Protein Tyrosine Phosphatase Receptor Type F (PTPRF) is downregulated upon miR-145 expression and may be involved in STAT1 regulation. In addition, we found that the STAT1-regulated protein IRF7 is downregulated in GBC compared to normal gallbladder tissue and low IRF7 expression is associated with significantly lower overall survival of GBC patients. Thus, this study identified GBC patient subgroups and provides new mechanistic insights in the tumor suppressive function of miR-145-5p leading to activation of STAT1 signaling.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University Hospital Heidelberg, Institute of Pathology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
2 Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany (GRID:grid.418245.e) (ISNI:0000 0000 9999 5706)
3 Friedrich-Alexander-University Erlangen-Nürnberg, Institute of Biochemistry, Emil-Fischer Zentrum, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)
4 University Hospital Heidelberg, Institute of Medical Biometry and Informatics, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
5 University Hospital Mannheim, Center of Medical Research, Mannheim, Germany (GRID:grid.411778.c) (ISNI:0000 0001 2162 1728)
6 University Hospital Heidelberg, Department of General Visceral and Transplantation Surgery, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
7 German Cancer Research Center (DKFZ), Genomics and Proteomics Core Facility, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
8 Heidelberg University Hospital, Institute of Pathology, Department of Neuropathology, Heidelberg, Germany and Clinical Cooperation Unit Neuropathology, German Cancer Research Center, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
9 Friedrich-Alexander-University Erlangen-Nürnberg, Institute of Biochemistry, Emil-Fischer Zentrum, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311); Friedrich-Alexander-University Erlangen-Nürnberg, Department of Medicine, Erlangen, Germany (GRID:grid.5330.5) (ISNI:0000 0001 2107 3311)